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DOI: 10.1039/c2py20112gReversible addition–fragmentation chain transfer (RAFT) polymerization was used to generate well-
defined pH-responsive biofunctional polymers as potential ‘smart’ gene delivery systems. A series of
five poly(dimethylamino ethyl methacrylate-co-cholesteryl methacrylate) P(DMAEMA-co-CMA)
statistical copolymers, with similar molecular weights and varying cholesterol content, were prepared.
The syntheses, compositions and molecular weight distributions for P(DMAEMA-co-CMA) were
monitored by nuclear magnetic resonance (NMR), solid-state NMR and gel permeation
chromatography (GPC) evidencing well-defined polymeric structures with narrow polydispersities.
Aqueous solution properties of the copolymers were investigated using turbidimetry and light
scattering to determine hydrodynamic diameters and zeta potentials associated with the phase
transition behaviour of P(DMAEMA-co-CMA) copolymers. UV-Visible spectroscopy was used to
investigate the pH-responsive behaviour of copolymers. Hydrodynamic radii were measured in the
range 10–30 nm (pH, temperature dependent) by dynamic light scattering (DLS). Charge studies
indicated that P(DMAEMA-co-CMA) polymers have an overall cationic charge, mediated by pH.
Potentiometric studies revealed that the buffering capacity and pKa values of polymers were dependent
on cholesterol content as well as on cationic charge. The buffering capacity increased with increasing
charge ratio, overall demonstrating transitions in the pH endosomal region for all five copolymeric
structures. Cell viability assay showed that the copolymers displayed increasing cytotoxicity with
decreasing number of cholesterol moieties. These preliminary results show the potential of these well-
defined P(DMAEMA-co-CMA) polymers as in vitro siRNA delivery agents.Introduction
Gene therapy research is a rapidly progressing field with vast
potential for the treatment of a variety of diseases including
muscular dystrophies, influenza, arthritis, osteoporosis, Alz-
heimer’s disease, asthma, cancer and AIDS.1–3 Small interfering
RNAs (siRNA), double-stranded products of 21–23 nucleotides,4
are vital agents in the RNA interference (RNAi) process, which is
aimed to specifically suppress a gene expression by breaking
down the target mRNA.5 siRNA has emerged as a promising
therapeutic strategy due to its target specific gene silencing
mechanism; however, its low in vivo stability and poor cellular
uptake hinder its therapeutic effect.6 To overcome these draw-
backs non-viral transfection vectors such as cationic polymers
have been developed to protect an siRNA and enhance its
intracellular delivery. Polycationic nonviral gene carriers benefitaAustralian Centre for Nanomedicine (ACN), The University of New
South Wales, Sydney, NSW 2052, Australia. E-mail: t.davis@unsw.edu.au
bDepartment of Chemical Engineering, Izmir Institute of Technology,
Gulbahce, _Izmir, 35430, Turkey
cChildren’s Cancer Institute Australia (CCIA), Lowy Cancer Research
Centre, The University of New SouthWales, Sydney, NSW 2052, Australia
This journal is ª The Royal Society of Chemistry 2012from greater flexibility, improved safety, and facile
manufacturing,7,8 as they offer advanced therapeutic efficacy
with doses of siRNA that are substantially lower and/or
delivered less frequently than otherwise.9 Synthetic cationic
polymers which have been used in gene transfection include
poly(ethylenimine) (PEI),10 poly(amidoamine) (PAMAM) den-
drimer,11 poly(histidine),12 poly(L-lysine),12,13 and chitosan.14
Specific physicochemical characteristics, such as chemical struc-
ture, pKa values, molecular weight and molecular weight distri-
bution, water solubility and architecture, must be taken into
account upon optimizing the transfection efficiency of cationic
polymers.15 ExGen 500, a linear PEI, has been developed as
a transfection reagent with a high transfection efficiency.16 In
comparison to branched PEI (25 kD), linear PEI (22 kD) has
exhibited superior proton sponge properties by inducing
membrane destabilization and facilitating the endosomal escape
of gene polyplexes.17,18 Consequently cationic polymers that are
able to protonate over a wider range of pH, similar to linear
PEI (22 kD), may display efficient gene delivery properties.
2-(Dimethylamino) ethyl methacrylate (DMAEMA), a tertiary
amine with low pKa, was chosen as the cationic component in our
copolymer structure. DMAEMA has been recognized for itsPolym. Chem., 2012, 3, 2057–2069 | 2057
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View Article Onlineability to complex and protect nucleotides while facilitating
endosomal escape through the proton sponge mechanism.19,20
Although cationic groups are primarily responsible for gene
binding and endosomal escape, when systemically administered
these positively charged complexes induce cytotoxicity. One
strategy to lower the cytotoxicity and enhance the stability of
polyplexes is to incorporate hydrophobic moieties.21
The enhancement of cell-membrane transport of therapeutics
can be achieved by using small hydrophobic and/or bulky lipid
groups, such as cholesterol, that can interact with cell
membranes.22Cholesterol is an essential structural component of
the plasma membrane, which is distributed heterogeneously,
where it typically accounts for 20–25% of the lipid molecules.23
Cholesterol participates in forming semipermeable barriers
between cellular compartments, regulates membrane fluidity,23
modulates the function of various membrane proteins,24,25 and
takes part in several membrane trafficking and trans-membrane
signaling processes.26 Cholesterol conjugation to an siRNA has
been described by others to enhance the cytoplasmic delivery of
an siRNA while eliciting RNA interference (RNAi), resulting in
specific gene silencing.27,28 Due to the proven effect of cholesterol
on the transport of therapeutics across the cell-membrane, we
have developed well-defined cholesterol containing, pH-respon-
sive, cationic polymers via reversible addition–fragmentation
chain transfer (RAFT) polymerization as potential carriers in
siRNA delivery applications.
RAFT is a living radical polymerization process invented by
CSIRO.29 As a synthetic technique, RAFT offers a convenient
platform for molecular engineering of polymeric systems for
drug delivery, biotechnology, nanotechnology and nanomedicine
applications.30–37 It has already been used to synthesise a range of
polymeric structures for siRNA delivery,38–46 with certain RAFT
generated polymers found to have low levels of cytotoxicity.47,48
In this study a novel polycationic system that is capable of self-
assembly in aqueous solutions and of forming small, stable
nanoparticles when complexed to siRNAs has been synthesized,
imbuing nonviral carrier characteristics such as gene protection,
phase transition and buffering capacity. A series of well-defined
P(DMAEMA-co-CMA) copolymers, with varying amounts of
CMA, were made and characterized.Experimental section
Materials
Cholesterol (Sigma, 98%), methacryloyl chloride (Fluka, >97%),
dichloromethane (Univar, analytical grade reagent), tetrahy-
drofuran (THF) (Univar, analytical grade reagent), toluene
(Univar, analytical grade reagent), dioxane (Univar, analytical
grade reagent), citric acid (Univar), methanol (Univar, analytical
grade reagent), acetone (Univar, analytical grade reagent),
ethanol (Univar, analytical grade reagent), sodium phosphate
monobasic (Univar), phosphate buffer saline (PBS) pellets
(Sigma), sodium phosphate dibasic (Univar), Roswell Park
Memorial Institute (RPMI) (Gibco, Invitrogen), Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco, Invitrogen), 10%
Fetal Calf Serum (FCS) were used as received. High purity
nitrogen (Linde gases, 99.99%) was used for purging the reaction
solutions before polymerization. 2-(Dimethylamino) ethyl2058 | Polym. Chem., 2012, 3, 2057–2069methacrylate (DMAEMA) monomer (Aldrich, 98%) was puri-
fied via basic alumina gel column chromatography before use.
The initiator, 2,2-azobisisobutyronitrile (AIBN), was recrystal-
lized twice from methanol prior to use. Triethylamine (Sigma-
Aldrich, 99%) was stored with sodium hydroxide pellets (Univar)
for 2 days prior to use. 4-(Cyanopentanoic acid)-4-dithio-
benzoate (CPADB), used as a RAFT agent, was synthesized
according to the procedure described in the literature.49,50 Ala-
marBlue dye was prepared by mixing 75 mg resazurin sodium
salt (Sigma), 12.5 mg methylene blue hydrate (Sigma), 164.5 mg
potassium hexacyanoferrate(III) (Sigma) and 211 mg potassium
hexacyanoferrate(II) trihydrate (Sigma) in 500 mL of sterile PBS.
Membranes for dialysis (MWCO 3500) were purchased from
Fisher Biotech (Cellu SepT4, regenerated cellulose-Tubular
membrane).Analytical techniques
Nuclear magnetic resonance (NMR) spectroscopy. 1H NMR
spectra were measured using a Bruker DPX 300 MHz spec-
trometer, while 13C NMR spectra were measured using a Bruker
Avance III 400MHzNMR Spectrometer. CDCl3 was used as the
solvent for solution state NMR analyses.
Solid-state nuclear magnetic resonance spectroscopy. The 13C
solid-state NMR spectra were recorded on a Bruker Avance III
300 MHz solid-state NMR spectrometer equipped with a 4 mm
standard bore cross-polarization magic angle spinning (CPMAS)
probe head. 100 mg of each polymer sample was packed down
into 4 mmMAS rotors, and analysed with the cross-polarization
procedure (CP) under magic angle spinning (MAS). 13C spectra
were recorded at a spinning frequency of 12 kHz.
Gel permeation chromatography (GPC). Gel permeation
chromatography was performed using HPLC grade dimethyla-
cetamide (DMAc) as themobile phase. Polymer solutions (3–5mg
mL1 inDMAc)were injected intoGPCat 40 C (flow rate¼ 1mL
min1). A Shimadzu modular system comprising an SIL-10AD
auto-injector, a PL 5.0mmbead-size guard column (50 7.8mm)
followed by four linear PL (Styragel) columns (105, 104, 103, and
100 A) was used. Calibration was achieved with commercial
polystyrene standards ranging from 500 to 106 g mol1.
Attenuated total reflection-Fourier transform infrared (ATR-
FTIR) spectroscopy. ATR-FTIR measurement was carried out
with a Bruker IFS66/S High End FT-NIR/IR Spectrometer
system using diffuse reflectance sampling accessories and a reso-
lution of 4 cm1. The monomer sample was analyzed using
256 scans.Methods
Cholesteryl methacrylate monomer synthesis. Cholesteryl
methacrylate (CMA) monomer was synthesized according to
a modified procedure in contradistinction to the literature.51,52 In
brief, cholesterol (2.0 g, 0.02 mol) was dissolved in the mixture of
toluene containing triethylamine (5 mL, 23% v/v triethylamine/
toluene) in a 100 mL round bottom flask with a stirrer bar. The
solution was left under reflux for 1 hour at 60 C. MethacryloylThis journal is ª The Royal Society of Chemistry 2012
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View Article Onlinechloride (3.3 mL, 0.60 mol) along with the remaining triethyl-
amine–toluene mixture (11.25 mL, 23% v/v triethylamine/
toluene) was added drop wise over a period of 30 minutes and the
solution was refluxed for an additional 12 hours. After the
solution reached room temperature the product, cholesteryl
methacrylate (CMA), was purified by precipitating in 1.6 NHCl–
methanol from toluene. The white colored precipitate, CMA,
was dried under vacuo overnight generating a yield of 88%
(Fig. 1).
1H NMR (CDCl3, d in ppm): 6.1, 5.5 (m, 2H, CH2]C(CH3)
COO-), 5.3 (d, 1H, J ¼ 4.9 Hz, -C]CH-, olefin group in
cholesterol), 4.6 (m, 1H, -COO-CH-), 1.9 (s, 3H, -CH2]C(CH3)
COO-), 0.93 (d, 3H, J¼ 6.6 Hz, -CH-CH3), 0.88, 0.84 (d, 3H, J¼
4.8 Hz, -CH-(CH3)2), 0.68 (s, 3H, -C-CH3).Fig. 1 (A) 1H NMR spectra of cholesteryl methacrylate monomer in CDCl3
solid-state NMR spectra on a Bruker Avance III 300 MHz solid-state NMR
This journal is ª The Royal Society of Chemistry 2012Solid-state 13C NMR (d in ppm): 162.5 (-COO-), 137.5 (-C]
CH-, olefin group in cholesterol), 134.7 (-CH2]C(CH3)COO-),
121.4 (-CH2]C(CH3)COO-), 119.2 (-C]CH-, olefin group in
cholesterol), 71.1 (-COO-CH-), 16.1 (-CH2]C(CH3)COO-).
ATR-FTIR (cm1): 3100–2700 (alkene and alkane C–H
stretching), 1716 (C]O stretching), 1639 (C]C stretching),
1160 (C–O–C stretching) (Fig. 2).
CMA monomer has been quantified in the literature with
a molar mass of 454 g mol1 (ref. 52) which has been confirmed
with the following elemental analysis: C%, 81.87; H%, 11.09;
O%, 7.04.53
Synthesis of poly(dimethylamino ethyl methacrylate). The
syntheses of poly(dimethylamino ethyl methacrylate)solvent using a Bruker 300 MHz NMR spectrometer, at 298 K; (B) 13C
spectrometer.
Polym. Chem., 2012, 3, 2057–2069 | 2059
Fig. 2 FT-IR spectra of cholesteryl methacrylate monomer.
Scheme 1 Synthesis of P(DMAEMA) via RAFT polymerization.
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View Article Online(PDMAEMA) (Scheme 1) were performed using varying feed
ratios and experimental conditions (Table 1). Briefly,
DMAEMA monomer (500 mg, 3.2 mmol), RAFT agent, 4-
(cyanopentanoic acid)-4-dithiobenzoate (CPADB), and initiator,
2,2-azobisisobutyronitrile (AIBN), were dissolved in toluene and
sealed in flasks. The solutions were purged with N2 (g) for 20
minutes in an ice bath. The solutions were then placed in an oil
bath at 70 C. The monomer conversions were determined by 1H
NMR analyses of the crude polymerization mixtures (Fig. 3).
1H NMR (CDCl3, d in ppm): 4.08 (t, 2H, J ¼ 11 Hz, -COO-
CH2-CH2-), 2.57 (t, 2H, J ¼ 11 Hz, -COO-CH2-CH2-), 2.30 (s,
6H, -N-(CH3)2), 1.86 (s, 2H, CH2-C-), 0.98 (s, 3H, -C-CH3).
The comparative molecular weights of the polymers were
obtained by GPC using DMAc as the mobile phase.
RAFT copolymerization of dimethylamino ethyl methacrylate
and cholesteryl methacrylate. Statistical copolymerizations of the
monomers were conducted (experimental details are shown in
Table 2). DMAEMA and CMAmonomers, CPADB, and AIBN
were dissolved in toluene. The solutions were sealed in vials with
rubber septa and thendegassed using nitrogen for 30minutes in an
ice bath. The polymerizations were carried out at temperatures of
68 C. The monomer conversions were determined by 1H NMR
analyses of the crude polymerization mixtures (Fig. 6).Table 1 Experimental conditions for polymerization of DMAEMA
[DMAEMA]/[RAFT]/[AIBN]a Solvent Time (h)
164.0/1.0/0.10 Dioxane 24
200.0/1.0/0.20 Dixoane 8
252.0/1.0/0.22 Dioxane 10
252.0/1.0/0.22 Toluene 10
200.0/1.0/0.20 THF 8
a Polymerization conditions, temperature 70 C. b Monomer conversion dete
by DMAc GPC analysis using PS standards. d Polydispersity index. e The t
conversion  MWmonomer, where [M]o, [RAFT]o, conversion, MWmonomer
conversion and molecular weight of the monomer respectively.
2060 | Polym. Chem., 2012, 3, 2057–20691HNMR (CDCl3, d in ppm): 5.38 (d, 1H, J¼ 4.9 Hz, -C]CH-,
olefin group in cholesterol), 4.51(m, 1H, -COO-CH-), 4.08 (t, 2H,
J ¼ 11 Hz, -COO-CH2-CH2-), 2.57 (t, 2H, J ¼ 12.2 Hz, -COO-
CH2-CH2-), 2.30 (s, 6H, -N-(CH3)2), 1.86 (s, 2H, CH2-C-), 0.98
(s, 3H, -C-CH3), 0.93 (d, 3H, J ¼ 6.6 Hz, -CH-CH3), 0.88–0.84
(d, 3H, J ¼ 4.8 Hz, -CH-(CH3)2), 0.68 (s, 3H, -C-CH3).
The comparative molecular weights of the polymers were
obtained by GPC using DMAc as the mobile phase. Copolymers
were purified by a two-step process; initially P(DMAEMA-co-
CMA) was dialyzed against a 98% ethanol–water mixture for 4
days. Samples were subjected to rotary evaporation (to remove
ethanol) and then freeze-dried (to remove water). Finally the
copolymers were dissolved in acidic aqueous solution (10 mM
HCl solution prepared with deionized water) and transferred to
dialysis tubing (MWCO: 3500). The solutions were dialyzed
against deionized water for 3 days followed by freeze-drying,
giving a light-pink powder. The final pure copolymers were
analysed by solid-state 13C NMR (Fig. 7).
Solid-state 13C NMR (d in ppm): 162.5 (-COO-), 137.5 (-C]
CH-, olefin group in cholesterol), 119.2 (-C]CH-, olefin group
in cholesterol), 71.1 (-COO-CH-), 59.7 (-COO-CH2-CH2-), 56.3
(-COO-CH2-CH2-), 43.8 (-N-(CH3)2), 16.1 (-CH2]C(CH3)
COO-).
Characterization of basicity and protonation. The buffering
capacity of P(DMAEMA-co-CMA) copolymers was investi-
gated via acid–base titrations using combined protocols
described elsewhere.15,54,55 Each polymer was made into an
aqueous solution (20 mL) at concentrations of 0.2 mg mL1.
Under continuous stirring, solutions were first titrated with 0.1
M NaOH until the pH value reached 11, and then back-titrated
with 0.1 M HCl. The pH was measured using a Metrohm Ion
Analysis 827 pH lab meter from MEPinstruments. All
measurements were carried out in duplicate at 25 C. Finally ‘pH
vs. volumeHCl’ plots were generated to characterize the pH profile
of each copolymer.
Optical density measurements. UV-Visible spectroscopy was
used to analyze the pH-responsive phase behaviors of polymers
by measuring the turbidity change of polymer solutions at
varying pH values.56 Citric-phosphate buffer solutions (0.1 M)
ranging from pH 3.0 to pH 7.4 were prepared. The ionic
strengths of the buffer solutions were adjusted to 0.1 M by the
addition of NaCl to yield isotonic solutions. Six different poly-
mer samples, P(DMAEMA-co-CMA) (0% CMA, cholesterol
mole content of 0% with number average molecular weightConversionb (%) Mn
c (g mol1) PDId Mn,theo
e
66 15 270 1.17 17 000
57 17 230 1.17 17 900
75 21 600 1.21 28 500
81 25 500 1.19 31 800
68 n/a n/a 21 300
rmined by 1H NMR. c The number average molecular weight determined
heoretical molecular weight calculated by Mn,theo ¼ ([M]o/[RAFT]o) 
are the initial monomer and RAFT agent concentrations, monomer
This journal is ª The Royal Society of Chemistry 2012
Fig. 3 1H NMR spectra of PDMAEMA in CDCl3 using a Bruker 300 MHz NMR spectrometer, at 298 K. Polymerization conditions were 8.3
M : 0.033 M : 7.16 mM [DMAEMA] : [RAFT] : [AIBN] at 70 C in toluene for 10 hours. Polymer conversions were calculated according to the
equation given as follows: ½ðÐ i=2Þ=ððÐ i=2Þ þ ðÐ d=2ÞÞ  100%. Solvent peaks are represented with the asterisk symbol (*).
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View Article Online(Mn)GPC of 26 800 g mol
1; 2% CMA, cholesterol mole content
of 2% with (Mn)GPC 21 900 g mol
1; 4% CMA, cholesterol mole
content of 4% with (Mn)GPC 23 500 g mol
1; 8% CMA,
cholesterol mole content of 8% with (Mn)GPC 21 800 g mol
1;
15% CMA, cholesterol mole content of 15% with (Mn)GPC
23 500 g mol1; 20% CMA, cholesterol mole content of 20%
with (Mn)GPC 20 400 g mol
1) were dissolved in buffer solutions
at 0.128 mmol mL1 concentration. The absorbance of each
polymer solution from acidic pH to neutral pH was detected by
a double beam UV-Vis Spectrophotometer (Hitachi, U-2800)
using UV solutions 2.1 software. Polymer solutions were
measured at 400 nm using quartz cuvettes. Assays were repeated
three times.
Dynamic light scattering (DLS). Dynamic light scattering
studies were performed using a Malvern Instruments Zetasizer
Nano ZS Instrument (Malvern, USA) equipped with a 4 mVHe–
Ne laser operating at l ¼ 633 nm, an avalanche photodiode
detector with high quantum efficiency, and an ALV/LSE-5003
multiple tau digital correlator electronics system. The polymer
sample solutions were prepared with appropriate buffers at 3 mg
mL1 concentration. All samples were measured by scanning 7Table 2 Data of copolymers prepared at varying compositions
[M]t
a [DMAEMA]/[CMA]/[RAFT]/[AIBN]
CMA in feed
(mol% of total monomer
4.15 247.0/5.03/1.00/0.22 2
4.15 238.7/12.5/1.00/0.22 4
4.15 231.8/20.1/1.00/0.22 8
4.15 214.3/37.7/1.00/0.22 15
4.15 202.0/50.3/1.00/0.22 20
a Total monomer concentration, polymerization conditions, solvent toluene a
c The number of average molecular weight determined by DMAc GPC analy
This journal is ª The Royal Society of Chemistry 2012times with each time of automatic measurement. Assays were
done in triplicate.
z-Potential measurements. z-Potential measurements were
performed using a Malvern Instruments Zetasizer NaNo ZS
Instrument (Malvern, USA) equipped with a 4 mV He–Ne laser
operating at l ¼ 633 nm, an avalanche photodiode detector with
high quantum efficiency, and an ALV/LSE-5003 multiple tau
digital correlator electronics system. The polymer sample solu-
tions were prepared with neutral and acidic buffers at 3 mg mL1
concentration. Readings were taken in Folded Capillary cells
DTS1060 (Malvern Instruments) and recorded in millivolts
(mV). All measurements were done in triplicate.
Determination of cell viability via AlamarBlue assay. Human
lung cancer (H460) cells and normal human foetal lung fibro-
blasts (MRC5) were used to assess polymer toxicity. H460 cells
were grown in Roswell ParkMemorial Institute (RPMI) medium
with HEPES and L-glutamine, while MRC5 cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5 g
L1 glucose and L-glutamine; both mediums were supplemented
with 10% Fetal Calf Serum (FCS). For the cell viability assay,)
Polymer composition
(CMA mole ratio) Conversionb (%)
Mn
c
(g mol1) PDId
2 73 21 900 1.14
4 93 23 500 1.18
8 86 21 800 1.12
15 94 23 500 1.12
20 89 20 400 1.19
nd temperature 68 C. b Monomer conversion determined by 1H NMR.
sis using PS standards. d Polydispersity index.
Polym. Chem., 2012, 3, 2057–2069 | 2061
Scheme 2 Synthesis of P(DMAEMA-co-CMA) via RAFT polymerization.
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View Article OnlineH460 and MRC5 cells were seeded in 96-well plates at final
concentrations of 2.5  103 cells mL1 and 5  103 cells mL1,
respectively, and grown at 37 C in 5% CO2 and 95% humidity
for 24 hours to ensure adherence. Upon surface attachment cells
were treated with polymer solutions at varying concentrations
from 0.005 mM to 50 mM and were further incubated for 72
hours. After the incubation period, 20 mL of AlamarBlue was
added to each well, and incubated for another 6 hours. Absor-
bance was measured by a Benchmark Plus Microplate Spectro-
photometer (Bio-Rad Laboratories) that uses the MPM-III
software program at 570 nmEx/595 nmEm. The percentage of
viability was calculated by comparing treated cells with positive
control cells representing 100% viability:
% Cell viability ¼ [(AP  AB)/(AC  AB)]  100
AP and AC are the absorbances of cells treated with polymer
solutions (at varying concentrations) and control cells (cells only
in media, positive control for 100% viability) respectively. AB is
the absorbance of blank wells (wells with media and polymer
treatment, no cells) where the values are similar to 10% Triton X-
100 treatment which corresponds to 0% viability. The treatments
were done with 5 replicates; overall the assay was repeated three
times using cells at different passage numbers.Results and discussion
Cholesteryl methacrylate monomer synthesis
Cholesteryl methacrylate (CMA) was synthesized at high yields
and purity. Complete NMR characterization of this product was
performed by solution state 1H NMR and 13C NMR along with
solid-state 13C NMR spectra confirming the expected product.Fig. 4 1H NMR spectra of P(DMAEMA-co-CMA) in CDCl3 solvent
using a Bruker 300 MHz NMR spectrometer, at 298 K. 2% CMA feed
composition. Polymerization conditions 4.07M : 0.08M : 0.017M : 3.58
mM [DMAEMA] : [CMA] : [RAFT] : [AIBN] at 68 C in toluene at
predetermined time points (1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 9 h, 12 h).Synthesis of poly(dimethylamino ethyl methacrylate)
Before performing copolymerizations of CMA with DMAEMA,
homopolymerizations of each monomer were studied under the
same conditions. To determine the optimal reaction conditions
to synthesize P(DMAEMA), different feed mole ratios of
[DMAEMA]/[RAFT]/[AIBN] were examined (Table 1). THF,
toluene and dioxane were the solvents selected to facilitate
polymerization of CMA and DMAEMA monomers in a homo-
geneous phase. Polymer conversions in dioxane were lower than
those in the corresponding toluene experiments. Solvent effects
on free radical polymerization reactions are notoriously difficult
to attribute to elementary events;57 suffice to say that dioxane is
an electron-donor solvent, with the potential to interact with the
electron-acceptor carbonyl group of DMAEMA.582062 | Polym. Chem., 2012, 3, 2057–2069According to the results, 252.0/1.0/0.22 ([DMAEMA]/
[RAFT]/[AIBN]) in toluene had the highest conversion. This
ratio with an overall feed concentration of 8.3 M : 0.033 M : 7.16
mM ([DMAEMA] : [RAFT] : [AIBN]) produced a polymer with
25 500 g mol1 molecular weight and a PDI of 1.19. Throughout
further investigations the feed concentration was halved to 4.15
M : 0.017 M : 3.58 mM ([DMAEMA] : [RAFT] : [AIBN])
intending to lower the (Mn)GPC and PDI whilst optimising the
chain end integrity of the polymer.
RAFT copolymerization and kinetic studies
Enhancement of cytoplasmic delivery of macromolecular thera-
peutics can be achieved by using lipid structures, such as
cholesterol – an important component of cell membranes,59 that
promote membrane tethering and endocytosis into endosomes
by interacting with the cell membrane.22We hypothesized that by
incorporating cholesterol units into pH-sensitive synthetic
polymers, the cell-membrane activity of cholesterol could be
tuned in a pH-dependent manner.
We thus used the RAFT technique to generate potential
siRNA carriers from well-defined pH-responsive, statistical
copolymers of DMAEMA with differing ratios of CMA, esteri-
fied cholesterol. P(DMAEMA-co-CMA) was prepared via
RAFT polymerization, usingCPABD, a dithioester RAFT agent
widely used amongst methacrylate polymerizations,60 and AIBN
as an initiator (Scheme 2).
Polymerizations were performed in toluene using 4.15 M as the
total monomer concentration, at a feed ratio of 4.07 M : 0.08
M : 0.017M : 3.58mM[DMAEMA] : [CMA] : [RAFT] : [AIBN]This journal is ª The Royal Society of Chemistry 2012
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View Article Onlineat 68 C, yielding a number average molecular weight
(Mn)GPC of 21 900 g mol
1 (polydispersity index (PDI) ¼ 1.14)
at a monomer conversion of 73%. The experimental
molecular weight determined by GPC was close to the theo-
retical value (i.e., 21 900–30 000 g mol1) calculated by
the equation Mn,theo ¼ ([M]o/[RAFT]o)  conversion 
MWmonomer, where [M]o, [RAFT]o, conversion, MWmonomer
are the initial monomer and RAFT agent concentrations,
monomer conversion and molecular weight of the monomer
respectively.
The polymerization kinetics of P(DMAEMA-co-CMA) (4.07
M : 0.08M : 0.017M : 3.58mM [DMAEMA] : [CMA] : [RAFT] :
[AIBN]) in toluene were monitored by 1H NMR at varying time
points (1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 9 h, 12 h) (Fig. 4). The overlayedFig. 5 Results from RAFT polymerizations of P(DMAEMA-co-CMA) in to
0.22). (A) GPC traces of P(DMAEMA-co-CMA) synthesized at different pol
Number average molecular weight (Mn)GPC (triangles) and PDI (circles) vs. m
This journal is ª The Royal Society of Chemistry 20121H NMR spectra depict the vinylic protons of both CMA and
DMAEMA decreasing with increasing time, indicative of the
expected result for a successful polymerization.
Fig. 5A displays the GPC traces of P(DMAEMA-co-CMA)
(obtained at [DMAEMA]/[CMA]/[RAFT]/[AIBN] ¼ 247.0/5.03/
1.00/0.22) suggesting the occurrence of a monomodal molecular
weight distribution during polymerization in toluene. It is evident
from GPC traces that the molecular weight of the P(DMAEMA-
co-CMA) increases with polymerization time. Fig. 5B reveals
a semi-logarithmicmonomer conversion (determinedby 1HNMR)
implying that monomer conversion increases concomitantly with
time. The advancement ofMn withmonomer conversion (Fig. 5C)
exhibits a linear pseudo-first order kinetic behavior with a narrow
polydispersity profile for the produced polymers. Consequently,luene at 68 C ([DMAEMA]/[CMA]/[RAFT]/[AIBN] ¼ 247.0/5.03/1.00/
ymerization times (from DMAc GPC); (B) Ln[M]o/[M] vs. time; and (C)
onomer conversion.
Polym. Chem., 2012, 3, 2057–2069 | 2063
Fig. 6 1H NMR of purified P(DMAEMA-co-CMA) (Mn determined by GPC, 23 500 g mol
1; and PDI 1.12) in CDCl3, obtained after dialysis against
98% ethanol–water mixture. Polymerization conditions 3.52 M : 0.622 M : 0.017 M : 3.58 mM [DMAEMA] : [CMA] : [RAFT] : [AIBN] at 68 C
in toluene for 9 hours. Copolymer compositions were determined by the 1H NMR spectrum resulting in CMA units: 20% mol; DMAEMA units:
80% mol. Copolymer composition was calculated according to the equation given as follows: CMA mol% ¼  Ð f =ðÐ c=2Þ þ ðÐ f Þ 100%;
DMAEMA mol% ¼ ðÐ c=2Þ=ðÐ c=2Þ þ ðÐ f Þ 100%.
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View Article Onlineboth narrowmolecularweight distributions and the linear increase
of molecular weights with monomer conversion indicate that the
RAFT polymerization of P(DMAEMA-co-CMA) displayed the
known traits of living radical polymerization.61
Purified polymers were analyzed by 1H NMR using CDCl3 as
the solvent (Fig. 6). Peaks at 5.3 and 4.5 ppm, indicative of
olefinic hydrogen in the cholesterol moiety and methine, –COO–Fig. 7 Solid-state 13C NMR of purified P(DMAEMA-co-CMA) (copolyme
obtained after reversible quarternization. Polymerization conditions 4.15 M
toluene for 9 hours.
2064 | Polym. Chem., 2012, 3, 2057–2069CH–, the main link between the cholesterol moiety and ester
group, were observed in equal intensities, suggesting good
polymerization with cholesterol units intact. Polymerization was
proven to be very efficient with the disappearance of signals at
6.15 and 5.60 ppm (ethylene group –H–) along with those at 6.10
and 5.56 ppm (olefin peaks), characteristic peaks of DMAEMA
and CMA respectively.r compositions 2% CMA, 4% CMA, 8% CMA, 15% CMA, 20% CMA)
: 0.017 M : 3.58 mM [total monomer] : [RAFT] : [AIBN] at 68 C in
This journal is ª The Royal Society of Chemistry 2012
Table 3 Buffering range and effective pKa values of statistical copoly-
mers of P(DMAEMA-co-CMA)
Polymer
Tertiary amine
content (%)
Buffering
range
Effective
pKa value
2% CMA 98 8.50–4.59 5.91
4% CMA 96 7.79–4.39 5.79
8% CMA 92 7.64–4.19 5.65
15% CMA 85 7.32–4.42 5.45
20% CMA 80 7.11–4.23 5.39
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View Article OnlineAfter confirming that DMAEMA and CMA can be readily
copolymerized under typical RAFT conditions, amphiphilic
statistical copolymers with increasing hydrophobic units were
prepared and further analyzed. A library of 8 statistical copol-
ymers was synthesized with CMA mol% of 2%, 4%, 8%, 15%,
20%, 30%, 40% and 50%. The amphiphilic character of copoly-
mers decreased with increasing cholesterol content making
reversible quarternization necessary to obtain particles in
aqueous solution. In accord with previous findings,62 copolymers
prepared with 20% CMA or less exhibited complete water solu-
bility and were chosen for further physicochemical analysis
(Table 2).
With the intention of confirming the molecular structure and
water solubility of quarternized copolymers, 1H NMR spectra
were examined in the presence of D2O. However, structure
visualization was hindered by D2O interfering with the sensitivity
and spectral resolutions of olefinic cholesterol peaks. As an
alternative technique, solid-state 13C NMR spectroscopy,
a powerful tool used for the investigation of various materials
such as polymers and, for the last decade, biomolecules,63 was
used for the characterization of copolymers, with evidential
success. The solid-state 13C NMR spectra portray efficient
polymerization with the disappearance of peaks at 134.7 ppm
and 121.4 ppm (CMA monomer signals) together with those at
136.0 ppm and 125.2 ppm (characteristic DMAEMA monomer
peaks) confirming the 1H NMR spectra. The spectrum allows
polymer compositions to be validated through integration ratios
between cholesterol peaks at 137.5 ppm and 119.2 ppm which
intensify with increasing CMA units (Fig. 7).Characterization of basicity and protonation
Buffering capacity is defined as the percentage of amine groups
becoming protonated over an 11 to 2 pH range. The buffering
capacity of potential gene carriers is a significant factor since the
property will have a direct impact on the ability to effectively
condense, protect and deliver genes.55,64 The presence of amine
units in our copolymers was expected to make them more
protonable over a broad pH range. Consequently,
P(DMAEMA-co-CMA) copolymers with varying cholesterol
content were examined by acid–base titrations. The profiles of
titration curves with hydrochloric acid (HCl) clearly revealed
that copolymers carrying more amine groups displayed a widerFig. 8 Potentiometric titration curves for statistical copolymers of 2%
CMA, 4% CMA, 8% CMA, 15% CMA and 20% CMA representing 2%,
4%, 8%, 15%, 20% mole ratio of CMA in P(DMAEMA-co-CMA)
respectively.
This journal is ª The Royal Society of Chemistry 2012buffering capacity (Fig. 8). Copolymers with 2% CMA showed
the strongest buffering ability, whereas copolymers with 20%
CMA showed the least buffering capacity.
Effective pKa values were calculated from the inflection points
of these titration curves (Table 3).65 The pKa values varied
between 5.39 and 5.91 which is less than pKa 7.4 (550 kD)–7.8
(4 kD) of PDMAEMA or of DMAEMAmonomer (pKa 8.4).
66,67
The shift to acidic pKa can be explained by the cholesterol units
contributing to an increase in the overall hydrophobicity.
Investigations suggest copolymers with greater hydrophobicity
manifest reduced dielectric constants influencing the deproto-
nation of amine groups, therefore displaying lower pKa values.
68
Results indicate that 2% CMA (lowest cholesterol units) in
comparison to 20% CMA (highest cholesterol units) exhibits
a higher pKa value, which is in agreement with previous
reports.15,69
Acid–base titrations show that the buffering capacity for
statistical P(DMAEMA-co-CMA) copolymers decreases with
increasing CMA content; their effective pKa values (5.39–5.91)
allow them to potentially protonate and become strong poly-
cations in the endosomal pH making them excellent candidates
to facilitate endosomal escape by the ‘‘proton sponge
effect’’.20,70–72Aqueous solution properties
Polymer chains equipped with ionisable units and hydrophobic
groups hold interesting pH-responsive properties when dissolved
in aqueous media.73 The pH-induced phase transitions of
P(DMAEMA-co-CMA) copolymers, in aqueous solutions, were
investigated by turbidity, light scattering and z-potential
measurements.Fig. 9 Absorbance values at 400 nm of P(DMAEMA-co-CMA) poly-
mers prepared with 0% CMA, 2%CMA, 4%CMA, 8%CMA, 15% CMA
and 20% CMA mole ratios, from acidic to neutral pH solutions at
0.125 mmol mL1.
Polym. Chem., 2012, 3, 2057–2069 | 2065
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View Article OnlineOptical density measurements. The turbidity profiles of
P(DMAEMA-co-CMA) copolymers, prepared with varying
CMA units, were observed in a range of pH 3.0–12.0. The
pH-dependent absorbance for the aqueous solutions of
P(DMAEMA-co-CMA) at 0.128 mmol mL1 (3 mg mL1)
were measured at 400 nm by UV-Vis spectrometry. In Fig. 9,
the turbidity changes of polymer solutions with increasing
hydrophobic units are shown from acidic to neutral pH.
Polymers carrying 0% CMA and 2% CMA retained trans-
parent solutions throughout the pH changes, evidencing the
absence of large scatter formation despite their pKa values. At
increased molar ratios of CMA, P(DMAEMA-co-CMA)
demonstrated significant elevation of absorbance at all values
of pH. The competitive interactions between electrostatic
repulsion and hydrophobic interactions seen in P(DMAEMA-
co-CMA) play a crucial role in determining the pH-dependent
phase transition of polymers in aqueous solution.73 Under
neutral conditions molecules seem to be relatively compact due
to their hydrophobic groups causing turbidity in solution.
Upon protonation of the amino groups in acidic pH, electro-
static repulsive forces take effect, expanding the polymer chain,
increasing its solubility and resulting in enhanced solvation.
Irregular absorbance patterns were displayed under basic
conditions suggesting the formation of unstable aggregates
(data not included).74
The pH-responsive turbidity profiles of P(DMAEMA-co-
CMA) copolymers are illustrated in two regions; the transparent
range where pH < pKa and the turbid range at pHz pKa or pH
> pKa. Fig. 9 reveals a drastic increase in absorbance for polymer
solutions between pH 4.5 and 6.5. This is attributed to both the
hydrophobic units arising from CMA and the enhanced hydro-
phobic effect emanating from the deprotonation of amine
groups. The effective pKa’s calculated from potentiometric
titration experiments revealed that increased hydrophobicity
(CMAmol% ratio) lowered the pKa values (2% CMA¼ 5.91, 4%
CMA¼ 5.79, 8% CMA¼ 5.65, 15% CMA¼ 5.45 and 20% CMA
¼ 5.39). As a result, P(DMAEMA-co-CMA) with the highest
hydrophobic ratio, 20% CMA, had the lowest pKa 5.39, subse-
quently demonstrating a phase transition at the lowest pH region
(pH z 5.0). Accordingly, with decreasing hydrophobic compo-
nents (<20% CMA) the pH region for phase transition exhibited
higher values (5.0 < pH < 6.0).Fig. 10 DLS results for copolymers with 2% CMA, 4% CMA, 8%
CMA, 15% CMA and 20% at different pH values (25 C). Anova
statistical error values show the results to be within * P < 0.005 accuracy.
2066 | Polym. Chem., 2012, 3, 2057–2069Dynamic light scattering and zeta-potential measurements. The
pH-induced aqueous solution behaviour of P(DMAEMA-co-
CMA) copolymers was further studied via DLS and zeta-
potential measurements. The effective diameter of each
copolymer in solution was investigated over the range pH 4.0 to
pH 10.0 at both 25 C and 37 C. It is evident from Fig. 10 that at
low pH values (pH < pKa) amine groups on DMAEMA
protonate, as indicated by transparent polymer solutions, with
consistent hydrodynamic radii. Upon shifting to higher pH
(>8.0), amine units begin to deprotonate and thus form unstable
aggregates.66,73,74 The effective diameter displayed by polymers in
aqueous solutions increased from 11 nm to 18 nm as the amount
of CMA increased from 2 to 20 mol%. In agreement with
previous research, particle size increases proportionally with the
hydrophobic (bulky) content in the copolymers (copolymers
containing 20% CMA exhibited the largest hydrodynamic
diameter).75 Increasing temperature had a slight effect by
enlarging their hydrodynamic radii (data not shown).
To determine the effective surface charge of P(DMAEMA-co-
CMA) copolymers, the zeta potential was measured at 2 different
pH values (pH 5.0 and 7.4) at 25 C as shown in Fig. 11, and at 37
C as shown in Table 4.
The zeta potentials of the copolymers increased from +27 mV
to +36 mV at pH 7.4 (25 C) and approached +47 mV from +38
mV at pH 5.0 (25 C) when the feed molar ratio of CMA units
decreased from 20% to 0%. This result is in accord with higher
charge densities in copolymers with less CMA (as expected). At
lower pH values, below the pKa point, the amine groups of
DMAEMA become protonated and increased the overall charge
density.76 Potentially, this protonation property of the copoly-
mers will help escape the acidified endosomes exploiting the
‘‘proton sponge effect’’.77
Cytotoxicity assay. The cytotoxicity profiles of P(DMAEMA-
co-CMA), prepared with varying CMA units, were evaluated by
an AlamarBlue Cell Viability Assay on both human lung cancer
(H460) cells and normal human foetal lung (MRC5) cells. Ala-
marBlue, an established cell viability indicator,78 benefits from
the reduction reactions that take place in metabolically active
cells where resazurin (nontoxic, non-fluorescent indicator dye) is
converted to resorufin, a bright red fluorescent molecule.79
Fig. 12 displays the viability of H460 and MRC5 cells after 72
hours as a function of polymer treatments at varying concen-
trations (0.005–50 mM).Fig. 11 z-Potential measurements of copolymers containing 0% CMA,
2% CMA, 4% CMA, 8% CMA, 15% CMA and 20% CMA under acidic
and neutral conditions (25 C). Anova statistical error values show the
results to be within * P < 0.0005 accuracy.
This journal is ª The Royal Society of Chemistry 2012
Table 4 z-Potential values for copolymers under acidic and neutral conditions at 37 C
Zeta potential (mV)
37 C 20% CMA 15% CMA 8% CMA 4% CMA 2% CMA 0% CMA
pH 5.0 22.07 21.27 38.83 40.27 40.63 38.43
pH 7.4 21.27 20.17 32.13 35.60 36.87 36.10
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View Article OnlineFor both carcinoma and healthy cell lines at concentrations
below 5 mM P(DMAEMA-co-CMA) copolymers displayed no
toxicity, demonstrating comparable cytotoxicity results with
cationic polymers like poly-L-lysine (PLL),80 poly(ethylenimine)
(PEI),21 poly(amidoamine) (PAMAM),80 and PDMAEMA.
Cationic polymers have received great attention, as they can
readily form stable nanostructures with nucleic acids and
mediate transfection with high efficacy whilst eluding difficulties
triggered by the use of viral vectors for gene delivery.81 However,
these molecules exhibit high cytotoxicity due to their cationic
nature. Some methods used to reduce toxicity have been (not
limited too) masking the charges and/or incorporating hydro-
phobic moieties.82 Taking this into consideration, P(DMAEMA-
co-CMA) copolymers have demonstrated lower toxicity (at
higher concentrations (5 mM)) with CMA units increased up to
15% and 20% (Fig. 12A). Copolymers with 2%, 4%, and 8%
CMA mole units displayed IC50 values of 1.5, 1.6, and 1.8 mM,
respectively, which are higher than those reported for the ‘gold
standard’ references PEI ((25 000 g mol1) (0.2–0.8 mM))21,83 andFig. 12 Viability of (A) human lung cancer H460 cells and (B) normal
human foetal lung (MRC5) cells after incubation with P(DMAEMA-co-
CMA) copolymers that consist of 2%, 4%, 8%, 15% and 20% CMA along
with P(DMAEMA) (0% CMA) for 72 hours, measured with AlamarBlue
assay. The assay was repeated three times in 5 replicates and the viability
results were normalized according to the positive control (untreated
cells). Error bars represent standard deviation. Anova statistical error
values show the results to be within * P < 0.005 accuracy.
This journal is ª The Royal Society of Chemistry 2012commercially available jetPEI (0.3 to 1.3 mM)84 in various cell
lines (HeLa, 4TI, MDAMB435). It should be stressed that
a maximum increase in cell viability (H460 cell line) was achieved
with copolymers of 15% and 20% CMA demonstrating (IC50
values of 5.0 and 21 mM respectively) the positive effect CMA
moieties had on polymer toxicity. The concentrations of copol-
ymers necessary for in vitro gene transfection studies are expected
to be lower than their IC50 values. The results potentially make
P(DMAEMA-co-CMA) useful cationic candidates for future
transfection studies.
Conclusion
In conclusion, a series of pH-responsive biosynthetic amphiphilic
copolymers of P(DMAEMA-co-CMA), with varying cholesterol
units, were synthesized via RAFT polymerization. The effect of
hydrophobic units on copolymer composition, self-assembly in
aqueous solutions and physicochemical properties was investi-
gated. Kinetics studies revealed well-defined polymeric structures
with narrow molecular weight distributions, indicating a living
RAFT polymerization. The copolymer compositions influenced
pKa values and consequently copolymer buffering capacity. The
amphiphilic copolymers showed pH-induced phase transitions in
aqueous media originating from protonation of the amine
groups as verified by turbidity, light scattering and zeta-potential
measurements. Cell viability assays revealed that the copolymers
displayed decreasing toxicity with increasing number of choles-
terol moieties.
The characterization of P(DMAEMA-co-CMA) copolymers,
reported herein, suggests that they are excellent candidates as
potential drug and gene carriers for pharmaceutical applications.
Future work will focus on in vitro studies on P(DMAEMA-co-
CMA) copolymers and will evaluate the copolymer utility for
condensing and transporting siRNA.
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